| pubmed-article:18628466 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18628466 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:18628466 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:18628466 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:18628466 | lifeskim:mentions | umls-concept:C0021017 | lld:lifeskim |
| pubmed-article:18628466 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:18628466 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:18628466 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:18628466 | lifeskim:mentions | umls-concept:C0005290 | lld:lifeskim |
| pubmed-article:18628466 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:18628466 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:18628466 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
| pubmed-article:18628466 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:18628466 | lifeskim:mentions | umls-concept:C1522326 | lld:lifeskim |
| pubmed-article:18628466 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:18628466 | pubmed:issue | 14 | lld:pubmed |
| pubmed-article:18628466 | pubmed:dateCreated | 2008-7-16 | lld:pubmed |
| pubmed-article:18628466 | pubmed:abstractText | To evaluate the role of microtubule-associated variables as potential predictors of response and clinical outcome in patients with advanced breast cancer receiving single-agent docetaxel or doxorubicin chemotherapy. | lld:pubmed |
| pubmed-article:18628466 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18628466 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18628466 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18628466 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18628466 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18628466 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18628466 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18628466 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18628466 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18628466 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18628466 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18628466 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:18628466 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:18628466 | pubmed:author | pubmed-author:PaesmansMaria... | lld:pubmed |
| pubmed-article:18628466 | pubmed:author | pubmed-author:DumontetCharl... | lld:pubmed |
| pubmed-article:18628466 | pubmed:author | pubmed-author:Di LeoAngeloA | lld:pubmed |
| pubmed-article:18628466 | pubmed:author | pubmed-author:DurbecqVirgin... | lld:pubmed |
| pubmed-article:18628466 | pubmed:author | pubmed-author:GancbergDavid... | lld:pubmed |
| pubmed-article:18628466 | pubmed:author | pubmed-author:LarsimontDeni... | lld:pubmed |
| pubmed-article:18628466 | pubmed:author | pubmed-author:PiccartMartin... | lld:pubmed |
| pubmed-article:18628466 | pubmed:author | pubmed-author:GalmariniCarl... | lld:pubmed |
| pubmed-article:18628466 | pubmed:author | pubmed-author:Bernard-Marty... | lld:pubmed |
| pubmed-article:18628466 | pubmed:author | pubmed-author:TreilleuxIsab... | lld:pubmed |
| pubmed-article:18628466 | pubmed:author | pubmed-author:CardosoFatima... | lld:pubmed |
| pubmed-article:18628466 | pubmed:author | pubmed-author:BisseryMarie-... | lld:pubmed |
| pubmed-article:18628466 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18628466 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:18628466 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:18628466 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18628466 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18628466 | pubmed:pagination | 4511-6 | lld:pubmed |
| pubmed-article:18628466 | pubmed:meshHeading | pubmed-meshheading:18628466... | lld:pubmed |
| pubmed-article:18628466 | pubmed:meshHeading | pubmed-meshheading:18628466... | lld:pubmed |
| pubmed-article:18628466 | pubmed:meshHeading | pubmed-meshheading:18628466... | lld:pubmed |
| pubmed-article:18628466 | pubmed:meshHeading | pubmed-meshheading:18628466... | lld:pubmed |
| pubmed-article:18628466 | pubmed:meshHeading | pubmed-meshheading:18628466... | lld:pubmed |
| pubmed-article:18628466 | pubmed:meshHeading | pubmed-meshheading:18628466... | lld:pubmed |
| pubmed-article:18628466 | pubmed:meshHeading | pubmed-meshheading:18628466... | lld:pubmed |
| pubmed-article:18628466 | pubmed:meshHeading | pubmed-meshheading:18628466... | lld:pubmed |
| pubmed-article:18628466 | pubmed:meshHeading | pubmed-meshheading:18628466... | lld:pubmed |
| pubmed-article:18628466 | pubmed:meshHeading | pubmed-meshheading:18628466... | lld:pubmed |
| pubmed-article:18628466 | pubmed:meshHeading | pubmed-meshheading:18628466... | lld:pubmed |
| pubmed-article:18628466 | pubmed:meshHeading | pubmed-meshheading:18628466... | lld:pubmed |
| pubmed-article:18628466 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18628466 | pubmed:articleTitle | Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. | lld:pubmed |
| pubmed-article:18628466 | pubmed:affiliation | Université Claude Bernard Lyon 1, France. | lld:pubmed |
| pubmed-article:18628466 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18628466 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:18628466 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:18628466 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
